Viking Therapeutics, Inc. (NASDAQ:VKTX) Q1 2024 Earnings Call Transcript
Q1 2024 Earnings Call Transcript April 24, 2024 Viking Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.26, expectations were $-0.27. Viking Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).
Viking Therapeutics Reports Q1 Results: 'An Exceptional Period' Says CEO
Viking Therapeutics, Inc. (NASDAQ:VKTX) reported its first-quarter financial results after the bell Wednesday. Here's a look at the highlights. The Details: Viking Therapeutics reported quarterly losses of 26 cents per share which beat the analyst consensus estimate of losses of 28 cents by 7.
Q1 2024 Viking Therapeutics Inc Earnings Call
Welcome to the Viking Therapeutics First Quarter 2024 financial results conference call. (Operator Instructions) As a reminder, this conference call is being recorded today, April 24, 2024. I would now like to turn the conference over to Viking's Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie.
Thomas Smith, an analyst from Leerink Partners, reiterated the Buy rating on Viking Therapeutics (VKTX – Research Report). The associated ...
In terms of liquidity and interest, the mean open interest for Viking Therapeutics options trades today is 1418.18 with a ...
Shares of Pfizer and Viking Therapeutics have been on markedly different trajectories over the prior three years. In this ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Viking Therapeutics (VKTX – Research Report) ...
While many bigger pharma names might desire entry into huge GLP-1 weight loss market, Pfizer makes logical sense on several ...
Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for Viking Therapeutics, ...
2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine ...
CRISPR Therapeutics ( CRSP -5.29%) and Viking Therapeutics ( VKTX -1.62%) are among the hottest mid-cap biotechs on the ...
An archive of the webcast will also be available on the Webcasts page of Viking's website for 30 days. About Viking Therapeutics, Inc. Viking Therapeutics, Inc. is a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results